TLR4 GENE FOUND TO PROTECT AGAINST TUMOR DEVELOPMENT

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



U.S. Department of Health and Human Services 
NATIONAL INSTITUTES OF HEALTH 
NIH News 
National Institute of Environmental Health Sciences (NIEHS)   
http://www.niehs.nih.gov/ 

FOR IMMEDIATE RELEASE: Wednesday, December 7, 2005  
 
CONTACT: Robin Mackar, 919-541-0073, rmackar@xxxxxxxxxxxxx
 
TLR4 GENE FOUND TO PROTECT AGAINST TUMOR DEVELOPMENT  

A new study finds that a gene which plays an important role in immune
function, known as toll-like receptor 4 (TLR4), may also play a critical
role in suppressing chronic lung inflammation and tumor development in
mice. 

"We know that chronic inflammation predisposes people to many types of
cancer," says NIH Director Elias Zerhouni, M.D. "By using this new
information we may be able to suppress chronic inflammation and reduce
our Nation's cancer burden." 

In the December 7, 2005 issue of the "Journal of the National Cancer
Institute", researchers at the National Institute of Environmental
Health Sciences (NIEHS), a part of the National Institutes of Health,
report that mice prone to lung cancer that had TLR4 removed or altered
had 60 percent more tumors than mice that had intact receptors,
illustrating a new protective role for this gene. There were no
differences in overall tumor size or structure between the mice. TLR4 is
part of what immunologists refer to as the "innate immune system" which
acts as the body's first line of defense against harmful substances. 

Researchers explain the immune system actually is comprised of two
components or systems, the innate and the acquired. The innate system
can be thought of as the way the body is naturally programmed to
respond, forming the front line of defense against infection. The
acquired depends on the development of antibodies and other systems to
recognize pathogens and other foreign objects that might upset the
body's ability to fight off diseases. Understanding more about how the
innate system works will help inform how the more complex, acquired
system works. 

"We have recently learned a lot about TLR4, its different mutations, and
the role they play in immunity," said David A. Schwartz, MD, the NIEHS
Director, "but discovering this novel function of TLR4 in tumor biology
may provide new therapeutic targets for many chronic diseases, including
cancer." 

"We can't attribute the number of tumors per mouse to TLR4 alone, but it
accounts for a significant portion of it," said Steven Kleeberger,
Ph.D., Chief, Laboratory of Respiratory Biology at NIEHS, where the
research was conducted. The researchers administered a preservative
known to cause lung inflammation to the mice to determine the role of
TLR4 in inflammation. Primary tumor formation also was measured in mice
known to have cancer. Mice with both functional and altered TLR4 were
used in all protocols. 

"TLR4 acts like a brake of a car," Kleeberger said. "If you take the
brake or receptor away, you see more increases in tumor development,
more inflammation and more mortality 

Previous research indicated an association between chronic lung
inflammation and lung cancer, but the mechanisms are not well
understood. Chronic bronchitis and asthma, for example, are known to
heighten the risk of lung cancer. Inflammation has been implicated as a
contributing factor in several human cancers, including lung cancer.
Therefore, researchers wanted to see if one of the well known receptors
in the immune system, the TLR4, played a role in the development of
cancer in an animal model. 

"What we found is the innate immune system, particularly TLR4, plays a
critical role in protecting against the development of tumors and
chronic inflammation," said Alison Bauer, Ph.D., of NIEHS and lead
author on the paper. "It suggests that targeting the innate immune
system may be a useful tool in fighting a variety of human diseases,
including cancer." 

"This mouse model provides us with the rationale to ask whether the
innate immune system might be involved in lung cancer in humans," said
Dr. Schwartz. "We are clearly finding that a better understanding of
innate immunity will provide us with new ways to fight off many
diseases." 

NIEHS, a component of the National Institutes of Health, supports
research to understand the effects of the environment on human health.
For more information on environmental health topics, please visit our
website at http://www.niehs.nih.gov/home.htm. 

The National Institutes of Health (NIH) -- "The Nation's Medical
Research Agency" -- includes 27 Institutes and Centers and is a
component of the U. S. Department of Health and Human Services. It is
the primary Federal agency for conducting and supporting basic,
clinical, and translational medical research, and it investigates the
causes, treatments, and cures for both common and rare diseases. For
more information about NIH and its programs, visit http://www.nih.gov.
  
##

------------------------------------
Reference: AK Bauer et al. Toll-Like Receptor 4 in Butylated
Hydroxytoluene-Induced Mouse Pulmonary Inflammation and Tumorigenesis.
"Journal of the National Cancer Institute"; Vol 97, No. 23, December 7,
2005.  
------------------------------------

This NIH News Release is available online at:
http://www.nih.gov/news/pr/dec2005/niehs-07.htm.

To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.

[Index of Archives]     [CDC News]     [FDA News]     [USDA News]     [Yosemite News]     [Steve's Art]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux